News|Videos|September 29, 2026 (Updated: September 29, 2026)
Iberdomide, Daratumumab, Dexamethasone vs Daratumumab, Bortezomib, Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma: Results From EXCALIBER-RRMM Phase 3 Study
The EXCALIBER-RRMM clinical trial evaluated a combination therapy of
iberdomide, daratumumab, and dexamethasone against daratumumab, bortezomib, and
dexamethasone in patients with relapsed or refractory multiple myeloma. The trial demonstrated
that adding the cereblon E3 ligase modulator iberdomide significantly improved minimal residual
disease-negative complete response rates across diverse patient subgroups while maintaining a
predictable and manageable safety profile. Based on these outcomes, the regulatory authority
granted accelerated approval for this treatment combination as a new standard of care for
patients experiencing early relapse.
Alissa Cooper, MD, reviews new data for established and emerging antibody-drug conjugate targets in non–small cell lung cancer and argues that payload innovation and better patient selection are the field's greatest needs.